tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2025 Dec;21(1):2448405.
doi: 10.1080/21645515.2024.2448405. Epub 2025 Jan 26. Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial
Siyue Jia[SUP] 1 [/SUP], Chengwei Shao[SUP] 2 [/SUP], Xin Cheng[SUP] 3 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Zhijian Wang[SUP] 4 [/SUP], Yu Xia[SUP] 3 [/SUP], Jianfang Xu[SUP] 4 [/SUP], Xuefen Huai[SUP] 3 [/SUP], Danjing Leng[SUP] 4 [/SUP], Jiarong Wang[SUP] 3 [/SUP], Gan Zhao[SUP] 3 [/SUP], Bin Wang[SUP] 3 [/SUP], Jingxin Li[SUP] 1 2 5 [/SUP], Fengcai Zhu[SUP] 1 2 5 [/SUP]
Affiliations
INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the occurrence of adverse events within 30 days after vaccination. A total of 781 volunteers were recruited and screened for eligibility, with 320 eligible young adults (≥18 to <60 years old) and 320 elderly (≥60 to ≤85 years old) were randomly assigned to receive the low-dose (1.0 mg, n = 120) or high-dose (2.0 mg, n = 120) INO-4800, or placebo (n = 80). Notably, both dose groups exhibited significant increases in spike-binding antibodies at day 30 after the second dose, with GMTs of 1609.3 (95% CI: 1385.5-1869.3) for the low-dose group and 3016.7 (95% CI: 2577.4-3530.8) for the high-dose group. Additionally, both dose groups induced neutralizing antibodies against live SARS-CoV-2, with GMTs of 4.7 (95% CI: 4.2-5.3) and 6.6 (95% CI: 5.9-7.4) at day 30 after the second dose. The incidence of adverse events within 30 days after vaccination was slightly higher in the high-dose group (115 [47.9%]) than that in the low-dose group (105 [43.8%]) (p = .0060). All adverse reactions were grade 1 or 2, primarily occurring within 14 days after vaccination. No vaccine-related serious adverse events were reported. The COVID-19 DNA vaccine INO-4800 at two doses (1.0 mg or 2.0 mg) showed an acceptable safety profile and modest immunogenicity, with the high-dose slightly more immunogenic than the low-dose.Clinical Trials Registration: www.chictr.org.cn, identifier is ChiCTR2000040146.
Keywords: COVID-19; DNA vaccine; immunogenicity; primary immunization; safety.
. 2025 Dec;21(1):2448405.
doi: 10.1080/21645515.2024.2448405. Epub 2025 Jan 26. Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial
Siyue Jia[SUP] 1 [/SUP], Chengwei Shao[SUP] 2 [/SUP], Xin Cheng[SUP] 3 [/SUP], Hongxing Pan[SUP] 1 [/SUP], Zhijian Wang[SUP] 4 [/SUP], Yu Xia[SUP] 3 [/SUP], Jianfang Xu[SUP] 4 [/SUP], Xuefen Huai[SUP] 3 [/SUP], Danjing Leng[SUP] 4 [/SUP], Jiarong Wang[SUP] 3 [/SUP], Gan Zhao[SUP] 3 [/SUP], Bin Wang[SUP] 3 [/SUP], Jingxin Li[SUP] 1 2 5 [/SUP], Fengcai Zhu[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 39865693
- DOI: 10.1080/21645515.2024.2448405
INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals. Eligible participants from each age group were enrolled and randomly assigned in a 3:3:2 ratio to receive two doses of INO-4800 (1.0 mg or 2.0 mg) or placebo, followed by electroporation on day 0 and day 28. The primary immunogenicity endpoints focused on determining the geometric mean titers (GMTs) of spike-binding antibodies and live SARS-CoV-2 neutralizing antibody at day 30 after the second dose. The primary endpoint for safety was the occurrence of adverse events within 30 days after vaccination. A total of 781 volunteers were recruited and screened for eligibility, with 320 eligible young adults (≥18 to <60 years old) and 320 elderly (≥60 to ≤85 years old) were randomly assigned to receive the low-dose (1.0 mg, n = 120) or high-dose (2.0 mg, n = 120) INO-4800, or placebo (n = 80). Notably, both dose groups exhibited significant increases in spike-binding antibodies at day 30 after the second dose, with GMTs of 1609.3 (95% CI: 1385.5-1869.3) for the low-dose group and 3016.7 (95% CI: 2577.4-3530.8) for the high-dose group. Additionally, both dose groups induced neutralizing antibodies against live SARS-CoV-2, with GMTs of 4.7 (95% CI: 4.2-5.3) and 6.6 (95% CI: 5.9-7.4) at day 30 after the second dose. The incidence of adverse events within 30 days after vaccination was slightly higher in the high-dose group (115 [47.9%]) than that in the low-dose group (105 [43.8%]) (p = .0060). All adverse reactions were grade 1 or 2, primarily occurring within 14 days after vaccination. No vaccine-related serious adverse events were reported. The COVID-19 DNA vaccine INO-4800 at two doses (1.0 mg or 2.0 mg) showed an acceptable safety profile and modest immunogenicity, with the high-dose slightly more immunogenic than the low-dose.Clinical Trials Registration: www.chictr.org.cn, identifier is ChiCTR2000040146.
Keywords: COVID-19; DNA vaccine; immunogenicity; primary immunization; safety.